Definium Therapeutics said its oral LSD-derived candidate DT120 eased anxiety symptoms in a second large Phase 3 trial, reinforcing its case for a regulatory submission for the first psychedelic medicine in anxiety. In the 12-week study, Definium reported a 9.8-point reduction on the Hamilton Anxiety Rating Scale with DT120 versus a 4.7-point drop with placebo, yielding a 5.1-point separation. The company highlighted rapid onset, reporting symptom changes as early as day two, and characterized the magnitude as consistent with earlier Phase 3 results for the program. Definium said it is preparing for an FDA submission pathway. For the category, the readout strengthens the late-stage evidence base for psychedelic-derived therapies in anxiety—an area that is beginning to attract regulatory attention amid stringent endpoints and safety requirements.